JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, N.
Right arrow Articles by Yang, Z.-j.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, N.
Right arrow Articles by Yang, Z.-j.
Journal of Nuclear Medicine Vol. 47 No. 2 242-246
© 2006 by Society of Nuclear Medicine

Clinical Investigation

Serum Concentrations of IL-2 and TNF-{alpha} in Patients with Painful Bone Metastases: Correlation with Responses to 89SrCl2 Therapy

Na Fang, MD1, Yong Li, MD1, Yan-song Xu, MB1, Duo Ma, MS1, Peng Fu, MS1, Hui-qi Gao, MS1, Feng-tong Gao, MB2, Hai-shan Yang, MB3 and Zhi-jie Yang, MB1

1 Department of Nuclear Medicine, First Hospital of HarBin Medical University, HarBin, China; 2 Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, ChangChun, China; and 3 Department of Radiology, China-Japan Union Hospital of Jilin University, ChangChun, China

Correspondence: For correspondence or reprints contact: Na Fang, MD, PET/CT Center, TianJin Cancer Hospital, TianJin, 300060, China. E-mail: fangna7859{at}163.com

We have used 89SrCl2 for the palliative treatment of painful bone metastases from various malignant diseases. We studied the correlation between serum interleukin-2 (IL-2) and tumor necrosis factor-{alpha} (TNF-{alpha}) levels and the response to 89SrCl2 therapy. Methods: Forty-two patients (24 men and 18 women) were treated intravenously with 89SrCl2 at a dose of 148 MBq (4 mCi). Results: The response rate was 33 of 42 (79%). In the control subjects, serum IL-2 concentrations were higher but TNF-{alpha} concentrations lower (P < 0.05) than in the patients with bone metastases. After treatment with 89SrCl2, IL-2 levels increased and TNF-{alpha} levels decreased, with maximal changes at the fourth month after therapy. After comparing the serum levels of IL-2 and TNF-{alpha} between responders and nonresponders, we found that these variables did not differ before 89SrCl2 therapy but differed significantly (P < 0.05) after therapy. Responders had higher IL-2 and lower TNF-{alpha} concentrations than nonresponders. A good correlation was found between IL-2 and TNF-{alpha} levels and the number of metastases and pain score. Conclusion: 89SrCl2 is effective for palliation of bone pain in patients with disseminated bone metastases. In addition to managing pain, 89SrCl2 can improve immunity and the quality of life for most patients. Further studies are needed to elucidate the roles of IL-2 and TNF-{alpha} in the response to 89SrCl2 therapy and to evaluate their usefulness as indicators of 89SrCl2 efficacy.

Key Words: 89SrCl2 • bone metastases • IL-2 • TNF-{alpha} • radionuclide therapy


Related articles in JNM:

This Month in JNM

JNM 2006 47: 7a-8a. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.